Shots:

• The P-III DARE-19 trial involves assessing the efficacy and safety of Farxiga vs PBO in addition to SoC therapy in 1-250 hospitalized patients with COVID-19 who are at high risk of developing serious complications
• The trial fails to meet its 1EP of prevention measures organ dysfunction- all-cause mortality- and recovery measuring a change in clinical status (from early recovery to death) @30days- safety and tolerability profile of Farxiga was consistent with the established safety profile of the therapy
• Farxiga (PO- qd) is an SGLT2 inhibitor- approved for HFrEF in adults with/out T2D. The results will be presented at ACC in May’2021

  Ref: AstraZeneca | Image: The Scientist Magazine